Dr Powles on EFS With Sasanlimab Plus BCG in BCG-Naive, High-Risk NMIBC

"Overall, I think it's fair to say that sasanlimab plus BCG works to prevent events in BCG-naive non–muscle-invasive [bladder] cancer. [Although] there might be some enrichment [in certain subgroups,] it seems to be working in a broader [patient] population as well."

Thomas Powles, MD, MBBS, MRCP, a professor of genitourinary oncology and director of Barts Cancer Centre at St. Bartholomew's Hospital, Queen Mary University of London, expanded on event-free survival data with sasanlimab in combination with BCG in BCG-naive, high-risk non–muscle-invasive bladder cancer, according to subgroup analyses based on disease stage from the phase 3 CREST study (NCT04165317).